Conduit Pharmaceuticals (CDT) announced that it has entered into a joint development agreement with Manoira Corporation, a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit’s AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational data across human and veterinary applications. Manoira will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to generate preclinical data that will better inform Conduit’s human clinical programs. This cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656’s mechanism of action, safety profile, and potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Sets 2025 Annual Meeting Date
- Conduit Pharmaceuticals approved to transfer listing to Nasdaq Capital Market
- Conduit Pharmaceuticals regains Nasdaq compliance
- Conduit Pharmaceuticals Inc trading halted, news pending
- Upcoming Stock Splits This Week (May 19 to May 23) – Stay Invested
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue